Comments
Lupin Ltd’s US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has launched the generic fenofibric acid delayed release capsules in 45 mg and 135 mg strengths.
These are the generic equivalent of AbbVie Inc.’s Trilipix indicated as co‐administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.
Trilipix delayed release capsules had yearly sales of around $449.5 million in the US, Lupin said in its filings with the stock exchanges.
The Lupin stock was up by Rs 11.40 to Rs 866.80 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.